Imexpharm CROIC

Cash Return on Invested Capital (CROIC) of Imexpharm is 1.08 % in 2026.

Cash Return on Invested Capital (CROIC) of Imexpharm changed from 5.27 % to 1.08 %, representing a -79.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).